Schmidt P J Investment Management Inc. lessened its stake in Amgen, Inc. (NASDAQ:AMGN) by 6.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,306 shares of the medical research company’s stock after selling 1,478 shares during the quarter. Schmidt P J Investment Management Inc.’s holdings in Amgen were worth $4,295,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the stock. Norges Bank bought a new position in Amgen in the fourth quarter valued at about $1,283,248,000. Thoroughbred Financial Services LLC grew its holdings in shares of Amgen by 19,447.3% during the second quarter. Thoroughbred Financial Services LLC now owns 1,805,392 shares of the medical research company’s stock worth $180,539,000 after purchasing an additional 1,796,156 shares during the last quarter. Ellis Investment Partners LLC grew its holdings in shares of Amgen by 18,906.7% during the first quarter. Ellis Investment Partners LLC now owns 605,934 shares of the medical research company’s stock worth $605,000 after purchasing an additional 602,746 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Amgen by 5.8% during the fourth quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock worth $1,720,250,000 after purchasing an additional 482,760 shares during the last quarter. Finally, Epoch Investment Partners Inc. grew its holdings in shares of Amgen by 536.5% during the fourth quarter. Epoch Investment Partners Inc. now owns 524,376 shares of the medical research company’s stock worth $102,080,000 after purchasing an additional 441,995 shares during the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.
In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $175.68, for a total value of $351,360.00. Following the transaction, the director now directly owns 16,219 shares of the company’s stock, valued at $2,849,353.92. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.25% of the stock is currently owned by insiders.
Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, July 30th. The medical research company reported $3.97 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.58 by $0.39. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The business had revenue of $5.87 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same period in the prior year, the business posted $3.83 earnings per share. The firm’s revenue was down 3.1% on a year-over-year basis. Equities analysts expect that Amgen, Inc. will post 14.23 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 6th. Shareholders of record on Thursday, August 15th will be paid a $1.45 dividend. This represents a $5.80 annualized dividend and a yield of 3.18%. Amgen’s dividend payout ratio (DPR) is presently 40.28%.
Several analysts have recently weighed in on the company. JPMorgan Chase & Co. restated a “hold” rating and set a $190.00 price target on shares of Amgen in a report on Wednesday, May 15th. Royal Bank of Canada restated a “neutral” rating and set a $192.00 price target on shares of Amgen in a report on Tuesday, May 21st. Oppenheimer set a $210.00 price target on Amgen and gave the stock a “buy” rating in a report on Friday, May 24th. Zacks Investment Research cut Amgen from a “buy” rating to a “hold” rating in a report on Monday, April 15th. Finally, Mizuho reiterated a “buy” rating and issued a $208.00 target price on shares of Amgen in a report on Monday, July 1st. Eight research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $210.41.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Read More: What is the Current Ratio?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.